Other languages ProQR Therapeutics N.V.

Equities

PRQR

NL0010872495

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-19 pm EDT			5-day change	1st Jan Change
1.99 ^USD	+6.99%		-9.55%	+0.51%

Mar. 14	Chardan Raises ProQR Therapeutics' PT to $2.50 From $2, Says ADAR-Based Therapeutics to Enter Clinical Development, Keeps Buy Rating	MT
Mar. 13	ProQR Therapeutics N.V. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

ProQR Therapeutics N.V. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 13
ProQR Therapeutics N.V. and Rett Syndrome Research Trust Join Forces with Axiomer RNA Editing Collaboration	Jan. 05
ProQR Therapeutics Completes Divestment of Two Ophthalmic Assets to Laboratoires Thea	Dec. 08
Laboratoires Théa S.A.S. acquired Sepofarsen and Ultevursen Ophthalmic Assets from ProQR Therapeutics N.V. for approximately ?170 million.	Dec. 06
ProQR Therapeutics N.V. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07
ProQR Therapeutics Granted US Patent Expanding Protection of RNA Editing Technology	Nov. 06
Laboratoires Théa S.A.S. cancelled the acquisition of Sepofarsen and Ultevursen Ophthalmic Assets from ProQR Therapeutics N.V..	23-09-26
ProQR Therapeutics N.V. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-03
ProQR Therapeutics N.V. Approves the Appointment of Theresa Heggie and Begoña Carreño as Supervisory Board Member	23-05-17
ProQR Therapeutics N.V. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-16
ProQR Therapeutics N.V. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-29
Proqr Therapeutics N.V. Announces Initial Pipeline Targets and Highlights Axiomer RNA Editing Platform Technology At R&D Event	23-03-29
ProQR Therapeutics Wins Hearing on Key Patent for Axiomer	23-03-14
ProQR Therapeutics N.V. Announces Successful Defense of Key Axiomer(R) Patent Protecting Adar-Mediated RNA Editing	23-03-14
Proqr Therapeutics N.V. and Eli Lilly and Company Enters into an Amended and Restated Research and Collaboration Agreement	22-12-23
Top Midday Gainers	22-12-22
Eli Lilly : élargissement de l'accord avec ProQR	22-12-22
Eli Lilly Expands Genetic Medicines Partnership with ProQR Therapeutics	22-12-22
Eli Lilly Expands Collaboration With ProQR on Development of New Genetic Medicines	22-12-22
Eli Lilly and Company and ProQR Therapeutics N.V. to Expand RNA Editing Collaboration	22-12-22

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages ProQR Therapeutics N.V.

Equities

PRQR

NL0010872495

Other languages

Filters